PET CT image of the Neck showing CA nasopharynx or carcinoma of nasopharynx from PET CT scannner.

PET CT image of the Neck showing CA nasopharynx or carcinoma of nasopharynx from PET CT scannner. Getty Images


January 11, 2022 — Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China. 

Clario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug efficacy evaluation. PET imaging has supported novel studies for Alzheimer's disease (AD) and other neurodegenerative diseases. A dedicated team of neuroscientists and project managers have led multiple trials in China to date. 

The new expanded offering leverages the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China, including amyloid, tau, and other targets.   

“Broadening our scope of clinical trials to further support drug development in neuroscience presents a unique opportunity for both patients and clinical researchers,” said Joyce Suhy, PhD, SVP Medical Imaging at Clario. “Our continued partnership with XingImaging is advancing therapeutics in APAC.” 

"XingImaging is proud to be working with Clario in providing PET imaging multi-center clinical trials,” said Gilles Tamagnan, CEO XingImaging, LLC. “Our partnership enables patients in China to participate in clinical trials testing novel neurodegenerative disease therapeutics." 

For more information: www.clario.com


Related Content

News | Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
News | PET Imaging

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Time December 01, 2022
arrow
News | Artificial Intelligence

December 1, 2022 — VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has announced the availability of ...

Time December 01, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 29, 2022 — Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that ...

Time November 29, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2022 — For the first time, a new study has identified enlarged perivascular spaces in the brains of ...

Time November 23, 2022
arrow
News | Pediatric Imaging

November 22, 2022 — A new MRI study revealed that consumption of alcohol even in low to moderate amounts during ...

Time November 22, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 17, 2022 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR) ...

Time November 17, 2022
arrow
News | Radiopharmaceuticals and Tracers

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
Videos | ASTRO

Dr. Frank A. Vicini, MD, FACR, FASTRO, FABS, who is a radiation oncologist with GenesisCare, discussed his findings from ...

Time November 09, 2022
arrow
Subscribe Now